CEO Arvid Söderhäll
General Manager: Patric Stenberg
Cadila Pharmaceuticals Sweden AB is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the World.
Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, biotechnology products, plant tissue culture and more than 38 APIs and intermediates. In the services realm, our offering includes Pre-Clinical and Clinical Research as well as Contract Manufacturing.
We have scientific collaborations with leading Swedish companies for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.
The Swedish office has been set up to ensure success of ongoing and future collaborations between Swedish companies and institutions, and our Indian organization. We encourage regional researchers and companies to get in touch with us to discuss potential collaborations or our service offerings.
NeuroVive Pharmaceutical AB was founded in 2000 with the aim of commercializing cyclosporine-based drugs for the treatment of acute traumatic conditions. Cyclosporine is able to reduce the level of secondary tissue damage following a traumatic injury by mitochondrial protection. NeuroVive went public in 2008 with an IPO on the Swedish AktieTorget exchange.